As we expected, anti-EGFR-GNs combined with NIR-PTT led to remarkably greater tumor regression compared to treatment with either anti-EGFR antibody alone or anti-EGFR-GNs alone, significantly reducing proliferation activity (low Ki-67 level) and inducing apoptotic activity (high cleaved caspase-3 and TUNEL levels) in sections of the MDA-MB-231 tumors. The gene discussed is CASP3; the disease is neoplasm.